National Institutes of Health
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
About This Grant
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Who Can Apply
Focus Areas
Additional Details
- CFDA / ALN Number
- 93.393
- Program Title
- Cancer Cause and Prevention Research
- Source
- Grants.gov · View original listing
Similar Grants
U.S. Mission to Cote d Ivoire
Freedom250 in Côte d’Ivoire American Spaces
$10K – $19KDue June 15, 2026U.S. Mission to Argentina
Grant Administration for Binational Centers (BNCs) in Argentina
$57K – $57KDue June 15, 2026Small Business Administration
Manufacturing in America E2G Grant Initiative
$5M – $5MDue June 15, 2026Center for Medicare and Medicaid Services
Make America Healthy Again – Enhancing Lifestyle and Evaluating Value-based Approaches Through Evidence
Up to $3.3MDue in 7 days — May 15, 2026Centers for Disease Control and Prevention - ERA
Occupational Safety and Health Education and Research Centers (T42)
$4.5M – $9MDue October 26, 2028National Institutes of Health
Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional)
Due May 8, 2027